Hellmann Worldwide Logistics

Hellmann Worldwide Logistics is a privately held global logistics provider headquartered in Osnabrück, Germany. Established in 1871, the company has expanded its operations to over 160 countries, offering a comprehensive range of services including air and ocean freight, road and rail transportation, contract logistics, and supply chain management.

In New Zealand, Hellmann Worldwide Logistics specializes in delivering on-time, temperature-sensitive international supply chain solutions to organizations within the agricultural, horticultural, seafood, and healthcare industries. Their services encompass warehousing, distribution, and logistics management, aiming to be an extension of their customers' businesses to ensure mutual longevity and success.

Hellmann Worldwide Logistics operates multiple facilities across New Zealand, including offices in Auckland, Lower Hutt, and Wellington. (cbaff.org.nz) Their logistics capabilities are designed to handle temperature-sensitive shipments, ensuring compliance with industry standards for the pharmaceutical sector. The company's geographic coverage extends throughout New Zealand, providing comprehensive supply chain solutions to meet the diverse needs of their clientele.

In New Zealand's pharmaceutical supply chain, Hellmann Worldwide Logistics functions primarily as a logistics intermediary. While they are not directly involved in the wholesale distribution or parallel importation of pharmaceutical products, their role is crucial in ensuring the efficient and compliant transportation and storage of pharmaceutical goods. Their expertise in handling temperature-sensitive shipments aligns with the stringent requirements of the pharmaceutical industry.

Hellmann Worldwide Logistics' sourcing from India reveals a high concentration, with a total import value of $3.7 million USD across 266 shipments, primarily consisting of three products: Aspirin ($1.9 million, 5.0% share), Salicylic ($1.2 million, 7.1% share), and Hydrocortisone ($618,000, 0.9% share). This concentration indicates a strategic choice to source specific pharmaceutical formulations from India, leveraging the country's manufacturing capabilities and cost advantages. The stability of this relationship is suggested by the consistent number of shipments over the period, reflecting a reliable supply chain partnership.

The resilience of Hellmann Worldwide Logistics' Indian supply chain is supported by a diversified portfolio of 429 unique pharmaceutical formulations. This diversity mitigates risks associated with dependency on a limited number of products. However, the heavy reliance on a single supplier, CIPLA LIMITED, which accounts for 97.1% of the shipments, poses potential risks. To enhance supply chain resilience, it would be prudent for Hellmann to consider engaging additional suppliers and diversifying their sourcing strategies.

Hellmann Worldwide Logistics' sourcing pattern positions them to offer a specialized range of pharmaceutical products, particularly in the analgesics, combination drugs, and corticosteroids categories. For Indian exporters, this presents an opportunity to become alternative suppliers by offering complementary products or enhancing the quality and reliability of existing offerings. Building a diversified supplier base can strengthen Hellmann's competitive position in the New Zealand market.

In New Zealand, the regulation of pharmaceutical imports is overseen by Medsafe, the New Zealand Medicines and Medical Devices Safety Authority. Medsafe administers the Medicines Act 1981 and associated regulations, ensuring that medicines imported into New Zealand meet safety, quality, and efficacy standards. The importation of controlled drugs is subject to additional regulations under the Misuse of Drugs Act 1975. (medsafe.govt.nz)

Importers of pharmaceutical products into New Zealand must comply with the Medicines Regulations 1984, which stipulate that all medicines must be securely packed to withstand transport and protect contents from damage. (legislation.govt.nz) Additionally, Good Manufacturing Practice (GMP) certification is required for pharmaceutical products. Medsafe recognizes GMP certificates from the European Union, World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), ensuring that imported medicines are manufactured to internationally recognized standards. (medsafe.govt.nz)

Imported pharmaceutical products must undergo batch testing to confirm their quality and compliance with New Zealand standards. Stability requirements ensure that medicines maintain their efficacy and safety throughout their shelf life. Labeling must be in English and include essential information such as dosage instructions, storage conditions, and expiry dates. Serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, New Zealand has implemented several policy changes affecting pharmaceutical imports. These include stricter regulations on the importation of controlled drugs, enhanced requirements for GMP certification, and updated labeling standards to improve transparency and consumer safety. Importers must stay informed about these changes to ensure compliance and maintain uninterrupted supply chains.

Hellmann Worldwide Logistics' focus on importing analgesics, combination drugs, and corticosteroids aligns with market demand in New Zealand for these therapeutic areas. Analgesics and antipyretics are essential for pain and fever management, combination drugs offer convenience and improved patient adherence, and corticosteroids are critical for treating inflammatory conditions. This strategic product selection positions Hellmann to meet the therapeutic needs of the New Zealand population effectively.

Hellmann Worldwide Logistics' sourcing strategy emphasizes generic pharmaceutical formulations, primarily from India, leveraging cost advantages and the country's manufacturing capabilities. This approach allows them to offer a diverse range of products while maintaining competitive pricing. India's compliance with international GMP standards further supports the quality and reliability of the sourced products.

Based on their product mix, Hellmann Worldwide Logistics serves the wholesale distribution segment of the New Zealand pharmaceutical market. By importing a range of pharmaceutical products, they supply these to various stakeholders, including retail pharmacies, hospitals, and healthcare providers, ensuring a steady and reliable supply of essential medicines.

There is a realistic opportunity for new Indian suppliers to engage with Hellmann Worldwide Logistics by offering complementary products not currently in their portfolio or by enhancing the quality and reliability of existing offerings. Diversifying the supplier base can strengthen Hellmann's competitive position and resilience in the New Zealand market.

Indian exporters seeking to supply Hellmann Worldwide Logistics and the New Zealand market must ensure that their products comply with New Zealand's regulatory requirements, including obtaining GMP certification recognized by Medsafe. Additionally, products must meet labeling standards, including English language requirements and necessary information such as dosage instructions and storage conditions. Engaging with Medsafe and staying informed about regulatory updates is essential for successful market entry.

Indian exporters should initiate contact with Hellmann Worldwide Logistics by presenting their product portfolio, emphasizing compliance with New Zealand's regulatory standards, and demonstrating the quality and reliability of their products. Participating in relevant tenders and industry events can enhance visibility and facilitate partnerships. Understanding the regulatory filing process and timelines for product registration with Medsafe is crucial to ensure timely market entry.